Myriad Genetics, Inc.
MYGN
$10.18
-$0.34-3.23%
| Weiss Ratings | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.44 | |||
| Price History | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -11.94% | |||
| 30-Day Total Return | -20.22% | |||
| 60-Day Total Return | -32.72% | |||
| 90-Day Total Return | -53.32% | |||
| Year to Date Total Return | -24.59% | |||
| 1-Year Total Return | -55.37% | |||
| 2-Year Total Return | -53.09% | |||
| 3-Year Total Return | -55.21% | |||
| 5-Year Total Return | -32.45% | |||
| 52-Week High % Change | -64.10% | |||
| 52-Week Low % Change | 7.79% | |||
| Price | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $29.30 | |||
| 52-Week Low Price | $9.76 | |||
| 52-Week Low Price (Date) | Feb 25, 2025 | |||
| 52-Week High Price (Date) | Sep 18, 2024 | |||
| Valuation | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 960.57M | |||
| Enterprise Value | 998.47M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.41 | |||
| Earnings Per Share Growth | -56.03% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.14 | |||
| Price/Book (Q) | 1.37 | |||
| Enterprise Value/Revenue (TTM) | 1.19 | |||
| Price | $10.18 | |||
| Enterprise Value/EBITDA (TTM) | -37.40 | |||
| Enterprise Value/EBIT | -11.36 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 91.10M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 801 584 3600 | |||
| Address | 322 North 2200 West Salt Lake City, UT 84116 | |||
| Website | www.myriad.com | |||
| Country | United States | |||
| Year Founded | 1991 | |||
| Profitability | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -10.49% | |||
| Profit Margin | -15.19% | |||
| Management Effectiveness | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -5.05% | |||
| Return on Equity | -- | |||
| Income Statement | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 837.60M | |||
| Total Revenue (TTM) | 837.60M | |||
| Revenue Per Share | $9.19 | |||
| Gross Profit (TTM) | 585.40M | |||
| EBITDA (TTM) | -26.70M | |||
| EBIT (TTM) | -87.90M | |||
| Net Income (TTM) | -127.30M | |||
| Net Income Avl. to Common (TTM) | -127.30M | |||
| Total Revenue Growth (Q YOY) | 7.12% | |||
| Earnings Growth (Q YOY) | -36.22% | |||
| EPS Diluted (TTM) | -1.41 | |||
| EPS Diluted Growth (Q YOY) | -27.80% | |||
| Balance Sheet | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 102.40M | |||
| Cash Per Share (Q) | $1.12 | |||
| Total Current Assets (Q) | 298.00M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 701.10M | |||
| Current Ratio (Q) | 1.816 | |||
| Book Value Per Share (Q) | $7.68 | |||
| Total Assets (Q) | 1.03B | |||
| Total Current Liabilities (Q) | 164.10M | |||
| Total Debt (Q) | 140.30M | |||
| Total Liabilities (Q) | 326.50M | |||
| Total Common Equity (Q) | 701.10M | |||
| Cash Flow | MYGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -11.90M | |||
| Cash from Financing (TTM) | -7.40M | |||
| Net Change in Cash (TTM) | -29.00M | |||
| Levered Free Cash Flow (TTM) | 13.31M | |||
| Cash from Operations (TTM) | -8.70M | |||
